Search
fidaxomicin (Dificid)
Indications:
- recurrent Clostridium difficile colitis after prior treatment with vancomycin [3] (FDA approved for adults & children >= 6 months)
- may be used 1st line for treatment of Clostridium difficile colitis [4]
Contraindications:
Pregnancy category: B
Safety in lactation: ?
Dosage:
- 200 PO BID with or without food for 10 days
Tablets: 200 mg
Oral Suspension
Pharmacokinetics:
- fidaxomicin is a substrate of P-glycoprotein
Adverse effects:
- nausea (11%)/vomiting
- headache
- abdominal pain (6%)
- diarrhea
Drug interactions:
- inhibitors of P-glycoprotein (cyclosporine) may increase plasma levels of fidaxomicin
Mechanism of action:
- inhibits RNA synthesis by inhibiting RNA polymerases
Interactions
drug adverse effects of macrolide(s)
General
macrolide (macrolide antibiotic)
Database Correlations
PUBCHEM correlations
References
- FDA NEWS RELEASE: May 27, 2011
FDA approves treatment for Clostridium difficile infection
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm
- Prescriber's Letter 18(7): 2011
New Drug: Fidaxomicin (Dificid)
Detail-Document#: 270710
(subscription needed) http://www.prescribersletter.com
- Geriatric Review Syllabus, 10th edition (GRS10)
Harper GM, Lyons WL, Potter JF (eds)
American Geriatrics Society, 2019
- NEJM Knowledge+ Gastroenterology
- HIGHLIGHTS OF PRESCRIBING INFORMATION
DIFICID (fidaxomicin) tablet, oral suspension
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213138lbl.pdf